Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: Study in healthy volunteers

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 31, Issue 2, 2006, Pages 87-96

  Popović, Jovan ^a   Mitic R ^a   Sabo, A ^a   Mikov, M ^a   Jakovljevic V ^a   Dakovic Svajcer K ^a  

^a UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

Bioequivalence; Convolution; Input rate; Spline; Verapamil

Indexed keywords

ISOPAMIL; VERAPAMIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSAGE FORM; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MATHEMATICAL MODEL; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION;

EID: 33746776239     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03191124     Document Type: Article

References (46)

1. Schomerus M., Spiegelhalder B., Stieren B., et al. (1976): Physiological disposition of verapamil in man. Cardiovasc. Res., 10, 605-612.
2. Singh B.N., Ellrodt G., Peter T.C. (1987): Verapamil: a review of its pharmacological properties and therapeutic use. Drugs, 15, 169-197.
3. Freedman S.B., Richmond D.R., Ashley J.J., et al. (1981): Verapamil kinetics in normal subjects and patients with coronary artery spasm. Clin. Pharmacol. Ther., 30, 644-652.
4. Somogyi A., Albrecht M., Kleims G., et al. (1981): Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br. J. Clin. Pharmacol., 12, 51-60.
5. Johnston A., Burgess C.D., Hamer J. (1981): Systemic availability of oral verapamil and effect on PR interval in man. Br. J. Clin. Pharmacol., 12, 397-400.
6. Eichelbaum M., Somogyi A., von Unruh G.E., et al. (1981): Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D, L-verapamil using stable isotope-labelled verapamil. Eur. J. Clin. Pharmacol., 19, 133-137.
7. Kates R.E., Keefe D.L., Schwartz J., et al. (1981): Verapamil disposition kinetics in chronic atrial fibrillation. Clin. Pharmacol. Ther., 30, 44-51.
8. Woodcock B.G., Rietbrock I., Vohringer H.F., Rietbrock N. (1981): Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships. Clin. Pharmacol. Ther., 29, 27-34.
9. McAllister R.G., Kirsten E.B. (1982): The pharmacology of verapamil: IV-kinetic and dynamic effects after single intravenous and oral doses. Clin. Pharmacol. Ther., 31, 418-426.
10. Kates R.E. (1983): Calcium antagonists. Pharmacokinetic properties. Drugs, 25, 113-124.
11. Hamann SR., Blouin R.A., McAllister R.G. (1984): Clinical pharmacokinetics of verapamil. Clin. Pharmacokinet., 9, 26-41.
12. Vicek J., Macek K., Hulek P., Bratova M., Fendrich Z. (1995): Pharmacokinetic parameters of verapamil and its active metabolite norverapamil in patients with hepatopathy. Arzneimittelforschung, 45, 146-149.
13. Krecic-Shepard M.E., Barnas C.R., Slimko J., Jones M.P., Schwartz J.B. (2000): Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J. Clin. Pharmacol., 40, 219-230.
14. Vogelgesang B., Echizen H., Schmidt E., Eichelbaum M. (2004): Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D- verapamil examined with a stable isotope technique. 1984. Br. J. Clin. Pharmacol., 58, pp. S796-803; discussion S804-6.
15. Sica D.A. (2005): Calcium chanel blocker class heterogeneity: select aspects of pharmacokunetics and pharmacodynamics. J. Clin. Hypertens., 7, 21-26.
16. Kovarik J.M. (2005): Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br. J. Clin. Pharmacol., 434-437.
17. Harapat S.R., Kates R.E. (1979): Rapid high-pressure liquid chromatographic analysis of verapamil in blood and plasma. J. Chromatogr., 170, 385-390.
18. Shapiro S.S., Wilk M.B. (1965): An analysis of variance test for normality (complete samples). Biometrika, 52, 591-611.
19. Bartlett M.S. (1937): Some examples of statistical methods of research in agriculture and applied biology. J. Royal Stat. Soc., Supp. 4.
20. Grizzle J.E. (1965): The two-period change-over design and its use in clinical trials. Biometrics, 21, 467-480.
21. Grizzle J.E. (1974): Correction. Biometrics, 30, 727.
22. Grieve A.P. (1982): The two-period changeover design in clinical trials. Correspondence. Biometrics, 38, 517.
23. Zintzaras E., Bouka P. (1999): Bioequivalence studies: biometrical concepts of alternative design and pooled analysis. Eur. J. Drug Metab. Pharmacokinet., 24, 225-232.
24. Westlake W.J. (1972): Use of confidence intervals in analysis of comparative bioavailability trials. J. Pharm. Sci., 61, 1340-1341.
25. Westlake W.J. (1973): Use of statistical methods in evaluation of in vivo performance of dosage forms. J. Pharm. Sci., 62, 1579-1589.
26. Westlake W.J. (1976): Symmetrical confidence intervals for bioequivalence trials. Biometrics, 32, 741-744.
27. Westlake W.J. (1977): Correspondence. Biometrics, 33, 759-760.
28. Westlake W.J. (1979): Statistical aspects of bioavailability trials. Biometrics, 35, 273-280.
29. Westlake W.J. (1981): Response. Biometrics, 37, 591-593.
30. Westlake W.J. (1988): Bioavailability and bioequivalence of pharmaceutical formulations. In: Peace K.E. (ed). Biopharmaceutical statistics for drug development. New York: Marcel Dekker, 329-352.
31. Spriet A., Beiler D. (1978): Table to facilitate determination of symmetrical intervals in bioavailability trials with Westlake's method. Eur. J. Drug Metab. Pharmacokin, 2, 129-132.
32. Rodda B.E., Davis R.L. (1980): Determining the probability of an important difference in bioavailability. Clin. Pharmacol. Ther., 28, 247-252.
33. Mandallaz D., Mau J. (1981): Comparison of different methods for decision making in bioequivalence assessment. Biometrics, 37, 213-222.
34. Selwin M.R., Dempster A.P., Hall N.R. (1981): A Bayesian approach to bioequivalence for the 2¥2 changeover design. Biometrics, 37, 11-21.
35. Selwin M.R., Hall N.R. (1984): On Bayesian methods for bioequivalence. Biometrics, 40, 1103-1108.
36. Anderson S., Hauck W.W. (1983): A new procedure for testing equivalence in comparative bioavailability and other clinical trials. Commun. Statist. Theor. Meth., 12, 2663-2692.
37. Hauck W.W., Anderson S. (1984): A new statistical procedure for testing equivalence in two-group comparative bioavailability trials. J. Pnarmacokin. Biopharm., 12, 83-91.
38. Schuirmann D.J. (1987): A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokin. Biopharm., 15, 657-680.
39. Koch G.G. (1972): The use of non-parametric methods in the statistical analysis of the two-period changeover design. Biometrics, 28, 577-584.
40. Popović J., Mikov M., Jakovljević V. (1992): Pharmacokinetics of ticlopidine derived from a new tablet formulation, Acta Biol. Med. Exp. 17, 49-52.
41. Popović J., Mikov M., Jakovljević V. (1993): Pharmacokinetics and systemic availability of a new metoprolol retard formulation., Eur. J. Drug Metab. Pharmacokinet., Special Issue.
42. Mikov M., Popović J., Jakovljević V. (1993): Metoxsalen bioavailability - the comparison of tablets and soft gelatine capsules., Eur. J. Drug Metab. Pharmacokinet., Special Issue.
43. Mikov M., Popović J. (1993): Availability and metabolism of paracetamol administered in the form of tablets or suppositories to healthy volunteers., Arch. Toxicol. Kin. Xen. Metab., 1, 61-68.
44. Popović J., Mikov M., Jakovljević V. (1994): Pharmacokinetic analysis of a new acenocoumarol tablet formulation during a bioequivalence study., Eur. J. Drug Metab. Pharmacokinet. 19, 85-89.
45. Popović J., Mikov M., Jakovljević V. (1995): Pharmacokinetics of carbamazepine derived from a new tablet formulation., Eur. J. Drug Metab. Pharmacokinet. 20, 297-300.
46. Stanulović M., Mikov M., Sabo A., Jakovljević V., Daković K., Popović J. (2000): Bioequivalence studies: experience on 55 studies, Int. J. Pharmaceutical Med., 14, 181.